Dec 06, 2025 • Investing.com Canada
NEUTRAL
P3 Health Partners and Commonwealth ACO form joint venture for value-based care
P3 Health Partners and Commonwealth ACO have formed a joint venture Management Services Organization (MSO) to broaden value-based care support for primary care physicians across five states. This strategic move aims to combine P3's expertise in Medicare Advantage and ACO models with Commonwealth's ACO REACH program, enhancing operational efficiency and support for independent physicians. Despite P3 Health Partners facing financial challenges, including a significant debt burden and recent revenue decline, this partnership is seen as a crucial opportunity for growth and market expansion, potentially improving their financial standing.
Dec 03, 2025 • Stock Titan
BULLISH
P3 Expands Footprint Through Joint Venture With Commonwealth Primary Care ACO
P3 Health Partners (NASDAQ: PIII) has formed a Joint Venture Management Services Organization (MSO) with Commonwealth Primary Care ACO to expand value-based care and support primary care physicians across multiple states. This partnership combines P3's expertise in Medicare Advantage and delegated risk with Commonwealth's ACO REACH program, creating a unified platform to enhance physician support and patient outcomes. The JV also extends P3's presence into Maricopa County, Arizona, strengthening its footprint in a key growth market.
Nov 17, 2025 • MarketBeat
SOMEWHAT-BEARISH
P3 Health Partners Q3 2025 Earnings Call Transcript
P3 Health Partners reported a Q3 2025 adjusted EBITDA loss of $45.9 million and revised its full-year adjusted EBITDA guidance to a loss between $95 million and $110 million, citing unfavorable settlement adjustments. Despite the financial setbacks, the company highlights a stable medical cost trend, improved capitated revenue per member per month, and an identified $120-$170 million EBITDA expansion opportunity for 2026, driven by operational improvements and strategic initiatives. Management remains confident in achieving meaningful profitability next year through core operating model execution and favorable market conditions.
May 15, 2025 • Business Wire
NEUTRAL
P3 Health Partners Announces First Quarter 2025 Results
P3 Health Partners Inc. announced its financial results for the first quarter ended March 31, 2025, affirming its 2025 guidance. The company reported a decrease in average at-risk membership but an increase in per-member funding, with total revenue at $373.2 million. Management highlighted progress on its turnaround plan, with three out of four markets achieving breakeven or better in Q1, and identified additional value creation opportunities.
Apr 03, 2025 • Investing.com UK
SOMEWHAT-BEARISH
P3 Health Partners approves reverse stock split By Investing.com
P3 Health Partners Inc. (NASDAQ: PIII) has approved a reverse stock split, ranging from 1-for-10 to 1-for-60, following a Special Meeting of Stockholders. This strategic move aims to optimize the company's capital structure amidst significant financial challenges, including a substantial debt-to-equity ratio and negative EBITDA, despite recent revenue growth and reaffirmed 2025 guidance. The stock has seen a nearly 77% decline over the past year.
Mar 27, 2025 • Business Wire
BEARISH
P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results
P3 Health Partners (NASDAQ: PIII) announced its financial results for the fourth quarter and full year ended December 31, 2024, affirming its 2025 guidance. The company reported an 18% year-over-year increase in total revenue to $1.50 billion for the full year, driven by growth in at-risk membership. Despite revenue growth, P3 Health Partners experienced increased net losses and adjusted EBITDA losses for both the quarter and full year, while projecting a significantly improved outlook for medical margin and adjusted EBITDA in 2025.